Alzheimer's disease drug development pipeline: 2017

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 3, Issue 3, 2017, Pages 367-384

  Cummings, Jeffrey ^a   Lee, Garam ^a   Mortsdorf, Travis ^b   Ritter, Aaron ^a   Zhong, Kate ^c  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c Global Alzheimer s Platform   (United States)

Author keywords

AD dementia; Alzheimer's disease; Biomarkers; Phase I; Phase II; Phase III; Preclinical AD; Prodromal AD

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; BEHAVIOR CHANGE; COGNITION; DRUG INDUSTRY; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

EID: 85020705963     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2017.05.002     Document Type: Review

References (42)

1. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11 (2015), 332–384.
2. Alzheimer's Association. Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars. 2015, Alzheimer's Association, Chicago, IL.
3. Cummings, J.L., Zhong, K., Chapter 17-symptomatic cognitive enhancing agents A2-Wolfe. Michael, S., (eds.) Developing Therapeutics for Alzheimer's Disease, 2016, Academic Press, Boston, 459–475.
4. Cummings, J., Morstorf, T., Lee, G., Alzheimer's drug development pipeline: 2016. Alzheimers Dement 2 (2016), 222–232.
5. Cummings, J., Aisen, P.S., DuBois, B., Frolich, L., Jack, C.R. Jr., Jones, R.W., et al. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther, 8, 2016, 39.
6. Hudson, K.L., Lauer, M.S., Collins, F.S., Toward a new era of trust and transparency in clinical trials. JAMA 316 (2016), 1353–1354.
7. Zarin, D.A., Tse, T., Williams, R.J., Carr, S., Trial reporting in clinicaltrials.gov - the final rule. N Engl J Med 375 (2016), 1998–2004.
8. Curry, S., DeCory, H.H., Gabrielsson, J., Phase I: the first opportunity for extrapolation from animal data to human exposure. Edwards, L.D., Fox, A.W., Stonier, (eds.) Principles and Practice of Pharmaceutical Medicine, 2011, Wiley-Blackwell, Oxford, UK, 84–106.
9. Kelley, J., Principles of CNS Drug Development: From Test Tube to Patient. 2009, Wiley-Blackwell, Oxford, UK.
10. Norfleet, E., Gad, S.C., Phase I clinical trials. Gad, C.S., (eds.) Clinical Trials Handbook, 2009, John Wiley & Sons, Inc., New York, New York, 245–254.
11. Gray, J.A., Fleet, D., Winblad, B., The need for thorough phase II studies in medicines development for Alzheimer's disease. Alzheimers Res Ther, 7, 2015, 67.
12. Tan, S.B., Machin, D., Phase II clinical trials. Gad, C.S., (eds.) Clinical Trials Handbook, 2009, John Wiley & Sons, Inc., New York, New York, 255–277.
13. Wang, S.J., Hung, H.M., O'Neill, R., Adaptive design clinical trials and trial logistics models in CNS drug development. Eur Neuropsychopharmacol 21 (2011), 159–166.
14. Cummings, J.L., Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 7 (2011), e13–e44.
15. Cummings, J.L., Zhong, K., Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Expert Rev Clin Pharmacol 7 (2014), 161–165.
16. Mattsson, N., Carrillo, M.C., Dean, R.A., Devous, M.D. Sr., Nikolcheva, T., Pesini, P., et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) 1 (2015), 412–419.
17. Sperling, R.A., Jack, C.R. Jr., Black, S.E., Frosch, M.P., Greenberg, S.M., Hyman, B.T., et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7 (2011), 367–385.
18. Viglietta, V., O'Gorman, J., Williams, L., Chen, T., Enayetallah, A., Chiao, P., et al. Titration dosing of aducanumab: results of a 12-month interim analysis from a randomized, double-blind, placebo-controlled phase 1b study (PRIME) in patients with prodromal or mild Alzheimer's disease (S7.003). Neurology, 88(S7.003), 2017, 16.
19. Appleby, B.S., Cummings, J.L., Discovering new treatments for Alzheimer's disease by repurposing approved medications. Curr Top Med Chem 13 (2013), 2306–2327.
20. Appleby, B.S., Nacopoulos, D., Milano, N., Zhong, K., Cummings, J.L., A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord 35 (2013), 1–22.
21. Jekunen, A., Decision-making in product portfolios of pharmaceutical research and development–managing streams of innovation in highly regulated markets. Drug Des Devel Ther 8 (2014), 2009–2016.
22. Gauthier, S., Feldman, H.H., Schneider, L.S., Wilcock, G.K., Frisoni, G.B., Hardlund, J.H., et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388 (2016), 2873–2884.
23. Zarin, D.A., Ide, N.C., Tse, T., Harlan, W.R., West, J.C., Lindberg, D.A., Issues in the registration of clinical trials. JAMA 297 (2007), 2112–2120.
24. De Angelis, C., Drazen, J.M., Frizelle, F.A., Haug, C., Hoey, J., Horton, R., et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 351 (2004), 1250–1251.
25. Babic, T., Riordan, H.J., Improving screen fail and recruitment rates in Alzheimer's disease clinical trials. J Clin Stud 8 (2016), 38–40.
26. Cummings, J., Reynders, R., Zhong, K., Globalization of Alzheimer's disease clinical trials. Alzheimers Res Ther, 3, 2011, 24.
27. Cummings, J.L., Aisen, P., Barton, R., Bork, J., Doody, R., Dwyer, J., et al. Re-engineering Alzheimer clinical trials: Global Alzheimer Platform Network. J Prev Alzheimers Dis 3 (2016), 114–120.
28. Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Green, R.C., et al. The Alzheimer's Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimers Dement 13 (2017), 561–571.
29. Menting, K.W., Claassen, J.A., Beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. Frontiers in Aging Neuroscience, 6, 2014, 165.
30. Hamada, Y., Kiso, Y., New directions for protease inhibitors directed drug discovery. Biopolymers 106 (2016), 563–579.
31. Evin, G., Future therapeutics in Alzheimer's disease: development status of BACE inhibitors. BioDrugs 30 (2016), 173–194.
32. Vassar, R., Kuhn, P.H., Haass, C., Kennedy, M.E., Rajendran, L., Wong, P.C., et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem 130 (2014), 4–28.
33. Hawkes, N., Merck ends trial of potential Alzheimer's drug verubecestat. BMJ, 356, 2017 j845.
34. Le Couteur, D.G., Hunter, S., Brayne, C., Solanezumab and the amyloid hypothesis for Alzheimer's disease. BMJ, 355, 2016 i6771.
35. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P.H., Williams, L., Maier, M., et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 537 (2016), 50–56.
36. Snyder, H.M., Hendrix, J., Bain, L.J., Carrillo, M.C., Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. Mol Aspects Med 43-44 (2015), 16–24.
37. Scott, T.J., O'Connor, A.C., Link, A.N., Beaulieu, T.J., Economic analysis of opportunities to accelerate Alzheimer's disease research and development. Ann N Y Acad Sci 1313 (2014), 17–34.
38. Cummings, J.L., Morstorf, T., Zhong, K., Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther, 6, 2014, 37.
39. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13 (2014), 419–431.
40. Refolo, L.M., Fillit, H.M., Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases. Curr Alzheimer Res 3 (2006), 175–176.
41. Fernandez, J.M., Stein, R.M., Lo, A.W., Commercializing biomedical research through securitization techniques. Nat Biotechnol 30 (2012), 964–975.
42. Lo, A.W., Ho, C., Cummings, J., Kosik, K.S., Parallel discovery of Alzheimer's therapeutics. Sci Transl Med, 6, 2014, 241cm5.